ALX Oncology to Host Virtual R&D Day on March 5, 2025

Core Insights - ALX Oncology will host a virtual Research and Development Day webcast on March 5, 2025, focusing on clinical program progress and business updates [1] - The event will provide updates on the company's pipeline and its lead investigational CD47-blocker, evorpacept, which is being evaluated in multiple clinical trials [2] Company Overview - ALX Oncology is a clinical-stage biotechnology company that develops therapies aimed at enhancing the immune system to treat cancer and improve patient survival [2] - Evorpacept, the company's lead therapeutic candidate, is positioned as a potential cornerstone therapy for future immuno-oncology treatments [2]